Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2471-2477

  Schiff, Michael ^a,e   Hochberg, Marc C ^b   Oldenhof, John ^c   Brune, Kay ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Kendle Early Stage   (Canada)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e NONE   (United States)

Author keywords

Aspirin; Naproxen sodium; Platelet inhibition; Thromboxane B2

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; NAPROXEN; NON PRESCRIPTION DRUG; PLACEBO; THROMBOXANE B2;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; ENZYME INHIBITION; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MORNING DOSAGE; NAUSEA AND VOMITING; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; NONPRESCRIPTION DRUGS; PLACEBOS; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; THROMBOXANE B2;

EID: 70349335690     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903185706     Document Type: Article

References (23)

1. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-162 (Pubitemid 351222155)
2. American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058-1073
3. Golden HE, Moskowitz RW, Minic M. Analgesic efficacy and safety of nonprescription doses of naproxen sodium compared with acetaminophen in the treatment of osteoarthritis of the knee. Am J Ther 2004;11:85-94 (Pubitemid 38879205)
4. Schiff M, Minic M. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee. J Rheumatol 2004;31:1373-1383 (Pubitemid 38879205)
5. Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 2004;63:1028-1034
6. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-1471 (Pubitemid 38420172)
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528 (Pubitemid 30844348)
8. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:1302-1308 (Pubitemid 44365384)
9. Henández-Diáz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006;98:266-274
10. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. J Am Med Assoc 2006;296:1633-1644 (Pubitemid 44511610)
11. Singh G, Wu O, Langhorne P, et al. Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006;8:R153
12. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with lumiracoxib, ibuprofen, or naproxen. Ann Rheum Dis 2007;66:764-770
13. Cryer B, Berlin RG, Cooper SA, et al. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther 2005;27:185-191 (Pubitemid 40462011)
14. Alessandrini P, Avagaro P, Bittolo BG, et al. Physiologic variables affecting thromboxane B2 production in human whole blood. Thromb Res 1985;37:1-8 (Pubitemid 15163069)
15. Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186
16. Catella F, Fitzgerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987;47:647-656 (Pubitemid 18032523)
17. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-1120
18. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001;48:339-346 (Pubitemid 32269561)
19. FDA Advisory Committee Background Information, presented to Arthritis Advisory Committee, February 8, 2001. Available at: http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3677b2-01-merck.pdf [Last accessed 11 May 2009]
20. Capone ML, Tacconelli S, Sciulli MG, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 2007;322:453-460
21. Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther 2008;46:180-186
22. Chou R, Helfand M, Peterson K, et al. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review No. 4. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.) Rockville, MD: Agency for Healthcare Research and Quality. September 2006. Available at: http://www.effectivehealthcare.ahrq.org/repFiles/ AnalgesicsFinal.pdf [Last accessed 11 May 2009]
23. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PLoS Clin Trials 2006;1:e33